Journal of Internal Medicine 2003; **254**: 609–612

Author index

Aanderud, S. *see* Nedrebø, B.G.
Abe, J.M. *see* Drager, L.F.
Ågren, L. *see* Lantz, H.
Åkerstedt, T. & Nilsson, P.M. Sleep as restitution: an introduction, 6
Aliberti, G., Pulignano, I., Schiappoli, A., Minisola, S., Romagnoli, E. & Proietta, M. Bone metabolism in ochronotic patients, 296
Andersson, C., Innala, E. & Bäckström, T. Acute intermittent porphyria in women: clinical expression, use and experience of exogenous sex hormones. A population-based study in northern Sweden, 176
Andersson, J. *see* Treutiger, C.J.
Andersson, R. *see* Suhr, O.B.
Andersson, U. *see* Treutiger, C.J.
Arand, D.L. *see* Bonnet, M.H.
Arnqvist, H.J. *see* Littorin, B.
Attvall, S. *see* Bonnier, M.
Aviel-Ronen, S. *see* Schattner, A.

Bäckström, T. *see* Andersson, C.
Barbey, F., Matthieu, C., Nseir, G., Burnier, M. & Teta, D. A young man with a renal colic, 605
Barranco, M. *see* Horcajada, J.P.
Bek, T. *see* Knudsen, S.T.
Belinki, A. *see* Ben-Ari, Z.
Ben-Ari, Z., Schmilovotz-Weiss, H., Belinki, A., Pappo, O., Sulkes, J., Neuman, M.G., Kaganovsky, E., Klir, B., Tur-Kaspa, R. & Klein, T. Circulating soluble cytochrome *c* in liver disease as a marker of apoptosis, 168
Bennermo, M., Held, C., Hamsten, A., Strandberg, L.-E., Ericsson, C.-G., Hansson, L.-O. & Tornvall, P. Prognostic value of plasma C-reactive protein and fibrinogen determinations in patients with acute myocardial infarction treated with thrombolysis, 244
Benseñor, I.J.M. *see* Drager, L.F.
Berne, C. *see* Tenerz, Å.
Berntorp, E. *see* Själander, A.
Bets, D. *see* Wulffelé, M.G.
Bie, P. *see* Jacobsen, P.
Bixler, E.O. *see* Vgontzas, A.N.
Björk, E. *see* Littorin, B.
Björkegren, K. & Svärdsudd, K. Reported symptoms and clinical findings in relation to serum cobalamin, folate, methylmalonic acid and total homocysteine among elderly Swedes: a population-based study, 343
Björntorp, P. *see* Rosmond, R.
Blanco-Vaca, F., López, N., Cuquet, J. & Mateo, J. Patient presenting multiple consecutive venous and arterial thrombotic events despite intensive conventional treatment: response after normalization of plasma homocysteine and *N*-acetylcysteine therapy, 397
Blohmé, G. *see* Littorin, B.
Bolinder, J. *see* Littorin, B.
Boman, H.G. Antibacterial peptides: basic facts and emerging concepts, 197
Bonanno, G. *see* Zoccali, C.
Bonnet, M.H. & Arand, D.L. Insomnia, metabolic rate and sleep restoration, 23
Bonnier, M., Lönnroth, P., Gudbjörnsdottir, S., Attvall, S. & Jansson, P.-A. Beneficial effect of glucose-insulin-potassium infusion in noncritically ill patients has to be proven – reply, 514
Borger van der Burg, B. *see* Wulffelé, M.G.
Bouchard, C. *see* Loos, R.J.F.
Brand, B. *see* Rydberg, E.
Britton, M. *see* Rödén-Jüllig, Å.
Buemi, M. *see* Zoccali, C.
Büller, H.R. *see* Koopman, M.M.W.
Burdeska, A. *see* Tankó, L.B.
Burnier, M. *see* Barbey, F.

Califf, R.M. Issues facing clinical trials of the future, 426
Calzoni, F. *see* Passaro, A.
Cameron, A.J. *see* Dalton, M.
Capecchi, P.L. *see* Laghi-Pasini, F.
Casiglia, E., Mazza, A., Tikhonoff, V., Scarpa, R., Schiavon, L. & Pessina, A.C. Total cholesterol and mortality in the elderly, 353
Christiansen, C. *see* Tankó, L.B.
Chrousos, G.P. *see* Vgontzas, A.N.
Cooper, C. *see* Souverein, P.C.
Cooper, E. *see* Vojdani, A.
Cuquet, J. *see* Blanco-Vaca, F.
Cutrupi, S. *see* Zoccali, C.
Czerwiński, E. *see* Tankó, L.B.

Dahlén, G. *see* Nordström, P.
Dalla Nora, E. *see* Passaro, A.
Dalton, M., Cameron, A.J., Zimmet, P.Z., Shaw, J.E., Jolley, D., Dunstan, D.W. & Welborn, T.A. on behalf of the AusDiab Steering Committee. Waist circumference, waist–hip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults, 555
Danielsson, Å. *see* Suhr, O.B.
Davies, R.J.O. *see* Meston, N.
De la Rosette, J.J.M.C.H. *see* Souverein, P.C.
De Valk-De Roo, G.W. *see* Duschek, E.J.J.
Dell'Omo, G., Giorgi, D., Di Bello, V., Mariani, M. & Pedrinelli, R. Blood pressure independent association of microalbuminuria and left ventricular hypertrophy in hypertensive men, 76
Devereaux, P.J. & Yusuf, S. The evolution of the randomized controlled trial and its role in evidence-based decision making, 105
Di Bello, V. *see* Dell'Omo, G.
Didjurgeit, U. *see* Sawicki, P.T.
Donker, A.J.M. *see* Wulffelé, M.G.
Drager, L.F., Abe, J.M., Martins, M.A., Lotufo, P.A. & Benseñor, I.J.M. Impact of clinical experience on quantification of clinical signs at physical examination, 257
Dunstan, D.W. *see* Dalton, M.
Duschek, E.J.J., Stehouwer, C.D.A., De Valk-De Roo, G.W., Schalkwijk, C.G., Lambert, J. & Netelenbos, C. Raloxifene, conjugated oestrogen and endothelial function in postmenopausal women, 85

Edvardsson, N., Juul-Möller, S., Ömblus, R. & Pehrsson, K. Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation, 95
Egberts, A.C.G. *see* Souverein, P.C.
Ehrenborg, E. *see* Skogsberg, J.
Eklund, A. *see* Katchar, K.
Engström, G. *see* Själander, A.
Erhardt, L. *see* Rydberg, E.
Ericsson, C.-G. *see* Bennermo, M.

© 2003 Blackwell Publishing Ltd

Eriksson, H. *see* Rosengren, A.
Eriksson, J.W. *see* Littorin, B.
Erlandsson-Harris, H. *see* Treutiger, C.J.

Fatuzzo, P. *see* Zoccali, C.
Fellin, R. *see* Passaro, A.
Felsenberg, D. *see* Tankó, L.B.
Forberg, R. *see* Tenerz, Å.
Ford, E.S. *see* Mannino, D.M.

Gadd, M., Johansson, S.-E., Sundquist, J. & Wändell, P. Morbidity in cardiovascular diseases in immigrants in Sweden, 236
Gans, R.O.B. *see* van der Horst, I.C.C.
Giorgi, D. *see* Dell'Omo, G.
Glader, C.A. *see* Nordström, P.
Gläser, B. *see* Sawicki, P.T.
Grunewald, J. *see* Katchar, K.
Gudbjörnsdottir, S. *see* Bonnier, M.
Guideri, F. *see* Laghi-Pasini, F.
Gullberg, B. *see* Littorin, B.
Gustafsson, D. Oral direct thrombin inhibitors in clinical development, 322

Hamsten, A. *see* Bennermo, M.
Hamsten, A. *see* Skogsberg, J.
Hansen, B.V. *see* Jacobsen, P.
Hansson, L.-O. *see* Bennermo, M.
Hastrup Svendsen, I. *see* Suhr, O.B.
Held, C. *see* Bennermo, M.
Held, P., Wedel, H. & Wilhelmsen, L. Clinical trials: introduction, 103
Hider, A. *see* Tønnesen, P.
Hiraishi, H. *see* Watanabe, H.
Hjalmarson, A. *see* Tønnesen, P.
Holm, G. *see* Rosmond, R.
Holm, P.I. *see* Nedrebø, B.G.
Holmgren, G. *see* Suhr, O.B.
Horcajada, J.P., Moreno, I., Velasco, M., Martínez, J.A., Moreno-Martínez, A., Barranco, M., Vila, J. & Mensa, J. Community-acquired febrile urinary tract infection in diabetics could deserve a different management: a case–control study, 280
van der Horst, I.C.C., Gans, R.O.B., Nijsten, M.W.N. & Ligtenberg, J.J.M. Beneficial effect of glucose-insulin-potassium infusion in noncritically ill patients has to be proven, 513
Hughes, C. *see* Tankó, L.B.
Hunt, B.J. *see* Kelly, J.
Hustad, S. *see* Nedrebø, B.G.

Innala, E. *see* Andersson, C.
Ishida, M. *see* Watanabe, H.

Jacobsen, P., Rossing, K., Hansen, B.V., Bie, P., Vaag, A. & Parving, H.-H. Effect of short-term hyperglycaemia on haemodynamics in type 1 diabetic patients, 464
Jansson, P.-A. *see* Bonnier, M.
Jenkinson, C. *see* Meston, N.
Jensen, A.O. & Mejer, J. Remission of methotrexate-resistant rheumatoid arthritis after receiving 5-fluorouracil for colon cancer, 395
Johansson, A.-S.M. *see* Treutiger, C.J.
Johansson, S.-E. *see* Gadd, M.
Jolley, D. *see* Dalton, M.
Jonasson, L., Tompa, A. & Wikby, A. Expansion of peripheral $CD8^+$ T cells in patients with coronary artery disease: relation to cytomegalovirus infection, 472
Jonkanski, I. *see* Tankó, L.B.
Juul-Möller, S. *see* Edvardsson, N.

Kaganovsky, E. *see* Ben-Ari, Z.
Kaiser, T. *see* Sawicki, P.T.
Karpe, F. *see* Skogsberg, J.
Katchar, K., Eklund, A. & Grunewald, J. Expression of Th1 markers by lung accumulated T cells in pulmonary sarcoidosis, 564
Kazama, J.J. *see* Watanabe, H.
Kelly, J. & Hunt, B.J. Do anticoagulants improve survival in patients presenting with venous thromboembolism? 527
Kesäniemi, Y.A. *see* Ukkola, O.
Kfir, B. *see* Ben-Ari, Z.
Kleespies, C. *see* Sawicki, P.T.
Klein, T. *see* Ben-Ari, Z.
Knudsen, S.T., Bek, T., Løgstrup Poulsen, P., Nørgaard Hove, M., Rehling, M. & Mogensen, C.E. Effects of losartan on diabetic maculopathy in type 2 diabetic patients: a randomized, double-masked study, 147
Koopman, M.M.W. & Büller, H.R. Short- and long-acting synthetic pentasaccharides, 335
Kooy, A. *see* Wulffelé, M.G.
Kraemer, D.M. & Kraus, M.R. Acquired factor VIII haemophilia in a patient with acute necrotic pancreatitis, 301
Kraus, M.R. *see* Kraemer, D.M.

Laghi-Pasini, F., Guideri, F., Petersen, C., Lazzerini, P.E., Sicari, R., Capecchi, P.L. & Picano, E. Blunted increase in plasma adenosine levels following dipyridamole stress in dilated cardiomyopathy patients, 591
Lambert, J. *see* Duschek, E.J.J.
Lantz, H., Peltonen, M., Ågren, L. & Torgerson, J.S. A dietary and behavioural programme for the treatment of obesity. A 4-year clinical trial and a long-term posttreatment follow-up, 272
Lazzerini, P.E. *see* Laghi-Pasini, F.
Lebargy, F. *see* Tønnesen, P.
Lee, A.Y.Y. & Vlasuk, G.P. Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor, 313
Lehert, P. *see* Wulffelé, M.G.
Leijd, B. *see* Rödén-Jüllig, Å.
Leppert, J. *see* Tenerz, Å.
Leufkens, H.G.M. *see* Souverein, P.C.
Li, W. *see* Nakanishi, N.
Lien, E.A. *see* Nedrebø, B.G.
Ligtenberg, J.J.M. *see* van der Horst, I.C.C.
Littorin, B., Nyström, L., Gullberg, B., Råstam, L., Östman, J., Arnqvist, H.J., Björk, E., Blohmé, G., Bolinder, J., Eriksson, J.W., Scherstén, B. & Sundkvist, G. Increasing body mass index at diagnosis of diabetes in young adult people during 1983–1999 in the Diabetes Incidence Study in Sweden (DISS), 251
Løgstrup Poulsen, P. *see* Knudsen, S.T.
Lönnroth, P. *see* Bonnier, M.
Loos, R.J.F. & Bouchard, C. Obesity – is it a genetic disorder? 401
López, N. *see* Blanco-Vaca, F.
Lorentzon, M. *see* Nordström, P.
Lorentzon, R. *see* Nordström, P.
Lotufo, P.A. *see* Drager, L.F.

McMahon, A.D. *see* Skogsberg, J.
Malatino, L.S. *see* Zoccali, C.
Mallamaci, F. *see* Zoccali, C.
Malmberg, K. *see* Tenerz, Å.
Malmkvist, K. *see* Rödén-Jüllig, Å.
Mannino, D.M., Ford, E.S. & Redd, S.C. Obstructive and restrictive lung disease and functional limitation: data from the Third National Health and Nutrition Examination, 540
Mariani, M. *see* Dell'Omo, G.

Mark, E.J. *see* Schattner, A.
Martin, L. *see* Rosmond, R.
Martínez, J.A. *see* Horcajada, J.P.
Martins, M.A. *see* Drager, L.F.
Mateo, J. *see* Blanco-Vaca, F.
Matthieu, C. *see* Barbey, F.
Mazza, A. *see* Casiglia, E.
Mejer, J. *see* Jensen, A.O.
Mensa, J. *see* Horcajada, J.P.
Meston, N., Davies, R.J.O., Mullins, R., Jenkinson, C., Wass, J.A.H. & Stradling, J.R. Endocrine effects of nasal continuous positive airway pressure in male patients with obstructive sleep apnoea, 447
Minisola, S. *see* Aliberti, G.
Mogensen, C.E. *see* Knudsen, S.T.
Mogensen, C.E. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes, 45
Moreno, I. *see* Horcajada, J.P.
Moreno-Martínez, A. *see* Horcajada, J.P.
Mosekilde, L. *see* Vestergaard, P.
Mullins, G.E. *see* Treutiger, C.J.
Mullins, R. *see* Meston, N.

Nakanishi, N., Nishina, K., Li, W., Sato, M., Suzuki, K. & Tatara, K. Serum γ-glutamyltransferase and development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men, 287
Nedrebø, B.G., Hustad, S., Schneede, J., Ueland, P.M., Vollset, S.E., Holm, P.I., Aanderud, S. & Lien, E.A. Homocysteine and its relation to B-vitamins in Graves' disease before and after treatment: effect modification by smoking, 504
Netelenbos, C. *see* Duschek, E.J.J.
Neuman, M.G. *see* Ben-Ari, Z.
Nicocia, G. *see* Zoccali, C.
Nijsten, M.W.N. *see* van der Horst, I.C.C.
Nilsson, G. *see* Tenerz, Å.
Nilsson, P.M. *see* Åkerstedt, T.
Nishina, K. *see* Nakanishi, N.
Nordström, P., Glader, C.A., Dahlén, G., Slunga Birgander, L., Lorentzon, R., Waldenström, A. & Lorentzon, M. Oestrogen receptor α gene polymorphism is related to aortic valve sclerosis in postmenopausal women, 140
Nørgaard Hove, M. *see* Knudsen, S.T.
Nseir, G. *see* Barbey, F.
Nyström, L. *see* Littorin, B.

Ogterop, J.C. *see* Wulffelé, M.G.
Öhrvik, J. *see* Tenerz, Å.
Olsen, M.L. *see* Vestergaard, P.
Ömblus, R. *see* Edvardsson, N.
Östman, J. *see* Littorin, B.

Paaske Johnsen, S. *see* Vestergaard, P.
Packard, C.J. *see* Skogsberg, J.
Palmblad, J.E.W. *see* Treutiger, C.J.
Pappo, O. *see* Ben-Ari, Z.
Pareschi, P.L. *see* Passaro, A.
Parlongo, S. *see* Zoccali, C.
Parving, H.-H. *see* Jacobsen, P.
Passaro, A., Calzoni, F., Volpato, S., Dalla Nora, E., Pareschi, P.L., Zamboni, P.F., Fellin, R. & Solini, A. Effect of metabolic control on homocysteine levels in type 2 diabetic patients: a 3-year follow-up, 264
Pedrinelli, R. *see* Dell'Omo, G.
Pehrsson, K. *see* Edvardsson, N.
Peltonen, M. *see* Lantz, H.
Pessina, A.C. *see* Casiglia, E.
Petersen, C. *see* Laghi-Pasini, F.
Pettersson, E. *see* Tryggvason, K.
Picano, E. *see* Laghi-Pasini, F.
Proietta, M. *see* Aliberti, G.
Pulignano, I. *see* Aliberti, G.

Ranløv, P.J. *see* Suhr, O.B.
Rapisarda, F. *see* Zoccali, C.
Råstam, L. *see* Littorin, B.
Rauvala, H.M.E. *see* Treutiger, C.J.
Redd, S.C. *see* Mannino, D.M.
Rehling, M. *see* Knudsen, S.T.
Rejnmark, L. *see* Vestergaard, P.
Rödén-Jüllig, Å., Britton, M., Malmkvist, K. & Leijd, B. Aspirin in the prevention of progressing stroke: a randomized controlled study, 584
Romagnoli, E. *see* Aliberti, G.
Ronquist, G. & Waldenström, A. Imbalance of plasma membrane ion leak and pump relationship as a new aetiological basis of certain disease states, 517
Rosengren, A., Eriksson, H., Welin, C. & Welin, L. Serum lipids in fathers and sons at middle age: the study of sons to men born in 1913, 126
Rosmond, R., Wallerius, S., Wanger, P., Martin, L., Holm, G. & Björntorp, P. A 5-year follow-up study of disease incidence in men with an abnormal hormone pattern, 386
Rossing, K. *see* Jacobsen, P.
Rouhiainen, A. *see* Treutiger, C.J.
Rydberg, E., Erhardt, L., Brand, B. & Willenheimer, R. Left atrioventricular plane displacement determined by echocardiography: a clinically useful, independent predictor of mortality in patients with stable coronary artery disease, 479

Sato, M. *see* Nakanishi, N.
Sawicki, P.T., Gläser, B., Kleespies, C., Stubbe, J., Schmitz, N., Kaiser, T. & Didjurgeit, U. Self-management of oral anticoagulation: long-term results, 515
Scarpa, R. *see* Casiglia, E.
Schalkwijk, C.G. *see* Duschek, E.J.J.
Schattner, A., Aviel-Ronen, S. & Mark, E.J. Accelerated usual interstitial pneumonitis, anti-DNA antibodies and hypocomplementemia, 193
Schattner, A. The essence of patient care, 1
Scherstén, B. *see* Littorin, B.
Schiappoli, A. *see* Aliberti, G.
Schiavon, L. *see* Casiglia, E.
Schmilovotz-Weiss, H. *see* Ben-Ari, Z.
Schmitz, N. *see* Sawicki, P.T.
Schneede, J. *see* Nedrebø, B.G.
Schulman, S. Novel anticoagulant agents: introduction, 308
Seminara, G. *see* Zoccali, C.
Shaw, J.E. *see* Dalton, M.
Sicari, R. *see* Laghi-Pasini, F.
Själander, A., Engström, G., Berntorp, E. & Svensson, P. Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general population, 434
Skogsberg, J., McMahon, A.D., Karpe, F., Hamsten, A., Packard, C.J. & Ehrenborg, E. on behalf of the West of Scotland Coronary Prevention Study. Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men, 597
Slunga Birgander, L. *see* Nordström, P.
Solini, A. *see* Passaro, A.
Souverein, P.C., Van Staa, T.P., Egberts, A.C.G., De la Rosette, J.J.M.C.H., Cooper, C. & Leufkens, H.G.M. Use of α-blockers and the risk of hip/femur fractures, 548
van Spiegel, P.I. *see* Tønnesen, P.
Stancanelli, B. *see* Zoccali, C.

Stehouwer, C.D.A. *see* Duschek, E.J.J.
Stehouwer, C.D.A. *see* Wulffelé, M.G.
Steiger, A. Sleep and endocrinology, 13
Stradling, J.R. *see* Meston, N.
Strandberg, L.-E. *see* Bennermo, M.
Stubbe, J. *see* Sawicki, P.T.
Suhr, O.B., Hastrup Svendsen, I., Andersson, R., Danielsson, Å., Holmgren, G. & Ranlov, P.J. Hereditary transthyretin amyloidosis from a Scandinavian perspective, 225
Sulkes, J. *see* Ben-Ari, Z.
Sundkvist, G. *see* Littorin, B.
Sundquist, J. *see* Gadd, M.
Suzuki, K. *see* Nakanishi, N.
Svärdsudd, K. *see* Björkegren, K.
Svensson, P. *see* Själander, A.
Sweet, R. *see* Tønnesen, P.

Tankó, L.B., Felsenberg, D., Czerwiński, E., Burdeska, A., Jonkanski, I., Hughes, C. & Christiansen, C. for the Oral Ibandronate Group. Oral weekly ibandronate prevents bone loss in postmenopausal women, 159
Tatara, K. *see* Nakanishi, N.
Tenerz, Å., Nilsson, G., Forberg, R., Öhrvik, J., Malmberg, K., Berne, C. & Leppert, J. Basal glucometabolic status has an impact on long-term prognosis following an acute myocardial infarction in non-diabetic patients, 494
Terano, A. *see* Watanabe, H.
Teta, D. *see* Barbey, F.
Thomas, C.R. *see* Zimmet, P.
Tikhonoff, V. *see* Casiglia, E.
Toft Sørensen, H. *see* Vestergaard, P.
Tompa, A. *see* Jonasson, L.
Tønnesen, P., Tonstad, S., Hjalmarson, A., Lebargy, F., van Spiegel, P.I., Hider, A., Sweet, R. & Townsend, J. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation, 184
Tonstad, S. *see* Tønnesen, P.
Torgerson, J.S. *see* Lantz, H.
Tornvall, P. *see* Bennermo, M.
Townsend, J. *see* Tønnesen, P.
Tracey, K.J. *see* Treutiger, C.J.
Treutiger, C.J., Mullins, G.E., Johansson, A.-S.M., Rouhiainen, A., Rauvala, H.M.E., Erlandsson-Harris, H., Andersson, U., Yang, H., Tracey, K.J., Andersson, J. & Palmblad, J.E.W. High mobility group 1 B-box mediates activation of human endothelium, 375
Tripepi, G. *see* Zoccali, C.
Tryggvason, K. & Pettersson, E. Causes and consequences of proteinuria: the kidney filtration barrier and progressive renal failure, 216
Tur-Kaspa, R. *see* Ben-Ari, Z.

Ueland, P.M. *see* Nedrebø, B.G.
Ukkola, O. & Kesäniemi, Y.A. Preproghrelin Leu72Met polymorphism in patients with type 2 diabetes mellitus, 391

Vaag, A. *see* Jacobsen, P.
Van Staa, T.P. *see* Souverein, P.C.
Velasco, M. *see* Horcajada, J.P.
Vestergaard, P. & Mosekilde, L. Fracture risk associated with smoking: a meta-analysis, 572
Vestergaard, P., Olsen, M.L., Paaske Johnsen, S., Rejnmark, L., Toft Sørensen, H. & Mosekilde, L. Corticosteroid use and risk of hip fracture: a population-based case–control study in Denmark, 486
Vgontzas, A.N., Bixler, E.O. & Chrousos, G.P. Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance, 32
Vila, J. *see* Horcajada, J.P.
VITAL Trial Collaborative Group. Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia, 67
Vlasuk, G.P. *see* Lee, A.Y.Y.
Vojdani, A., Vojdani, E. & Cooper, E. Antibodies to myelin basic protein, myelin oligodendrocytes peptides, α-β-crystallin, lymphocyte activation and cytokine production in patients with multiple sclerosis, 363
Vojdani, E. *see* Vojdani, A.
Vollset, S.E. *see* Nedrebø, B.G.
Volpato, S. *see* Passaro, A.

Waldenström, A. *see* Nordström, P.
Waldenström, A. *see* Ronquist, G.
Wallerius, S. *see* Rosmond, R.
Wändell, P. *see* Gadd, M.
Wanger, P. *see* Rosmond, R.
Wass, J.A.H. *see* Meston, N.
Watanabe, H., Hiraishi, H., Ishida, M., Kazama, J.J. & Terano, A. Pathophysiology of gastric acid secretion in patients with chronic renal failure: influence of *Helicobacter pylori* infection, 439
Wedel, H. *see* Held, P.
Welborn, T.A. *see* Dalton, M.
Welin, C. *see* Rosengren, A.
Welin, L. *see* Rosengren, A.
Wikby, A. *see* Jonasson, L.
Wilhelmsen, L. *see* Held, P.
Willenheimer, R. *see* Rydberg, E.
Wulffelé, M.G., Kooy, A., Lehert, P., Bets, D., Ogterop, J.C., Borger van der Burg, B., Donker, A.J.M. & Stehouwer, C.D.A. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial, 455

Yang, H. *see* Treutiger, C.J.
Yusuf, S. *see* Devereaux, P.J.

Zamboni, P.F. *see* Passaro, A.
Zimmet, P. & Thomas, C.R. Genotype, obesity and cardiovascular disease – has technical and social advancement outstripped evolution?, 114
Zimmet, P.Z. *see* Dalton, M.
Zoccali, C., Mallamaci, F., Tripepi, G., Cutrupi, S., Parlongo, S., Malatino, L.S., Bonanno, G., Rapisarda, F., Fatuzzo, P., Seminara, G., Stancanelli, B., Nicocia, G. & Buemi, M. Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure, 132

Journal of Internal Medicine 2003; **254**: 613–614

Keyword index

acute intermittent porphyria, 176
acute myocardial infarction, 244, 494
adenosine, 591
adrenergic alpha-antagonists, 548
ageing, 13
albuminuria, 76
alkaptonuria, 296
Alzheimer's disease, 517
amyloidosis (hereditary), 225
antibody, 363
anticoagulant(s), 313, 322, 335, 527
anticoagulation, 308
anti-DNA antibodies, 193
aortic valvular sclerosis, 140
apoptosis, 168
aspirin, 67, 584
association study, 597
ATPase, 517
atrial fibrillation, 95
AVPD, 479

benefit assessment, 426
BIBR 1048, 322
blood pressure, 46, 386
Body Mass Index, 251, 555
body size, 555
bone markers, 159
bone metabolism, 296
bone mineral density, 159, 296
bronchoalveolar lavage, 564
bupropion sustained release, 184

CAD, 479
cancer, 308, 353
candidate genes, 401
cardiovascular, 353
cardiovascular disease, 114, 386
cardiovascular disorders, 236
cardiovascular risk, 132
case–control study/studies, 280, 486, 548
cathelicidins, 197
cecropins, 197
chemokine receptors, 564
cholesterol metabolism, 597
chronic renal failure, 439
clinical signs, 257
clinical trials, 426
cobalamin, 343
coronary artery disease, 472
coronary heart disease, 236, 597
corticosteroids, 486
cortisol, 386, 494
cost-effectiveness, 426
Cox regression, 494
C-reactive protein, 132, 244
current smoker, 572
cytochrome *c*, 168
cytokine, 375
cytokine production, 363
cytomegalovirus, 472

daytime sleepiness, 32
deep vein thrombosis, 527
defensins, 197
dementia, 67
depression, 13
diabetes, 46, 114, 280, 386, 455
diabetes mellitus, 464, 494
diabetic maculopathy, 147
diabetic nephropathy, 147
diabetic retinopathy, 147
diagnosis, 257
dialysis, 132
dipyridamole, 591
direct thrombin inhibitor, 322
drop-out, 272

echocardiography, 591
endogenous antibiotics, 197
endothelin, 85
endothelium-dependent vasodilation, 85
endotoxin, 375
epidemiology, 353, 486
essential hypertension, 76
ethnic groups, 236
evidence-based medicine, 105, 426

factor VIIa, 313
factor Xa inhibitor, 335
familial risk, 401
febrile urinary tract infection, 280
fibrinogen, 132, 244
fibromuscular dysplasia, 605
folate, 343, 455, 504
fracture, 486
fracture risk, 572
functional limitation, 540

gastric acidity, 439
gastrin, 439
genetic polymorphisms, 140
genetic testing, 401
genetics, 401
geographical variation, 572
glomerular basement membrane, 216
glycaemic control, 264

haemoglobin A1c, 494
haemorrhagic stroke, 434
HbA_{1c}, 264
health status, 540
heritability, 126
hierarchies of evidence, 105
high mobility group 1, 375
hip fractures, 548
homocysteine, 67, 264, 343, 455, 504
hormones, 13, 447
H. pylori, 439
human, 353
human umbilical venular endothelial cells, 375
hyperglycaemia, 464
hypertension, 46, 605
hyperthyroidism, 504
hypogonadism, 447

ibandronate, 159
immune system, 472
immunology, 6
impaired fasting glucose, 287
inborn errors of metabolism, 225
incidence, 236, 251, 287
inflammation, 132, 308, 375
innate immunity, 197
insomnia, 23
insulin, 455
insulin resistance, 32
interleukin-6, 32
interleukin-12, 564
interleukin-18 receptors, 564
interstitial lung disease, 193
investigation approach, 257
ion leak, 517
ion pumping, 517
ionophore, 517
islet cell antibodies, 251

left ventricular hypertrophy, 76
liver disease, 168
LL-37, 197
long-term treatment, 272
losartan, 147
low-dose warfarin and aspirin, 95
lung function, 540
lung T cells, 564
lymphocyte proliferation, 363

macroangiopathy, 391
macular oedema, 147
medical decision, 257
men, 386
metabolic rate, 23
metabolism, 6
metformin, 455
methylentetrahydrofolate reductase polymorphism, 264
methylmalonic acid, 343
microalbuminuria, 46, 76
miscarriage, 176
mood, 23
morbidity, 236
morbus Kostmann, 197
mortality, 479
multiple sclerosis, 363
Multiple Sleep Latency Tests, 23

non-diabetic, 494

obesity, 114, 272, 401, 555
obstructive lung disease, 540
ochronosis, 296
oestrogen, 85
once-weekly dosing, 159
optical coherence tomography scanning, 147
oral anticoagulation, 434
osteoporosis, 296

pentasaccharide, 335
peptide-based defence, 197
peptides, 13
peroxisome proliferator activated receptor delta, 597
personality, 23
pharmacoepidemiology, 548
physical examination, 257
plasma membrane, 517

© 2003 Blackwell Publishing Ltd

platelet function, 67
podocyte, 216
polymorphism, 597
population, 353
population study, 126
positional cloning, 401
postmenopause, 85
PPAR, 114
preproghrelin, 391
prevention, 159
previous smoker, 572
prions, 517
prognosis, 479
progression, 584
prospective, 386
proteinuria, 216
psychomotor performance, 23
public health, 6
pulmonary embolism, 527

quantification of clinical signs, 257

raloxifene, 85
randomized controlled trial(s), 105, 184
recombinant nematode anticoagulant protein c2, 313
renal function, 391
renal infarction, 605
renin–angiotensin system, 464
respiratory symptoms, 540
restrictive lung disease, 540
riboflavin, 504
risk, 236, 353, 486
risk assessment, 426
risk factors, 126

sarcoidosis, 564
serum cholesterol, 126
serum γ-glutamyltransferase, 287
serum Japanese men, 287
sex hormone, 176
sleep, 13, 23
sleep apnoea, 32, 447
slit diaphragm, 216
smoking, 504, 572
smoking cessation, 184
soluble, 168
spirometry, 540
steroids, 13
stress, 591
stroke, 584
stroke prevention, 95
survey, 343
Sweden, 236
symptoms, 343
syndrome X, 517
systemic blood pressure, 464
systemic lupus erythematosus, 193

T lymphocytes, 472
Tarui's disease, 517
testosterone, 386
therapeutics, 426
thrifty genotype, 114
thrombolysis, 244
thrombosis, 308, 313
tissue factor, 313
transplantation (liver and heart), 225
transthyretin, 225
treatment attendance, 272
tumour necrosis factor-α, 32
type 1, 464
type 1 diabetes, 251
type 2 diabetes, 147, 251, 264, 287, 391

uremia, 132
urolithiasis, 605
usual interstitial pneumonitis, 193

variation, 391
venous thromboembolism, 527
very low calorie diet, 272
visceral obesity, 32
vitamin B12, 455
vitamin K antagonist, 322
vitamins, 67
von Willebrand factor, 85

waist circumference, 555
waist–hip ratio, 555
warfarin, 322, 434
weight gain, 184
withdrawal symptoms, 184
women, 140, 176

ximelagatran, 322

year of diagnosis, 251